NCT04657991 2026-04-07A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaPfizerPhase 3 Active not recruiting257 enrolled
NCT05203172 2026-04-07The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsPfizerPhase 4 Recruiting46 enrolled
NCT03915951 2026-03-24An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerPfizerPhase 2 Completed98 enrolled 18 charts 2 FDA
NCT04585815 2026-01-09Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)PfizerPhase 1/2 Terminated34 enrolled 44 charts
NCT04607421 2025-08-14A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPfizerPhase 3 Active not recruiting831 enrolled 5 FDA
NCT05743036 2025-08-08ZN-c3 in Adult Participants With Metastatic Colorectal CancerK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncPhase 1 Terminated44 enrolled